NCT02702492 (PANAMA) is a Phase 1 clinical trial of KPT-9274 in Solid Tumors, sponsored by Karyopharm Therapeutics Inc.

Who is sponsoring NCT02702492?

NCT02702492 is sponsored by Karyopharm Therapeutics Inc.

What drugs are being tested in NCT02702492?

Interventions in NCT02702492: KPT-9274, Niacin ER, Nivolumab.

What condition does NCT02702492 study?

NCT02702492 studies Solid Tumors, NHL.

Is NCT02702492 still recruiting?

NCT02702492 is currently terminated. Last updated 25 November 2024.

Are results published for NCT02702492?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-11-25 · How we verify

NCT02702492: PANAMA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

Terminated Phase 1 Results posted Last updated 25 November 2024

What this trial tests

Phase 1 trial testing KPT-9274 in Solid Tumors in 60 participants. Terminated before completion.

Timeline

8 June 2016

Primary endpoint
26 January 2021

26 January 2021

Quick facts

Lead sponsor	Karyopharm Therapeutics Inc
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	8 June 2016
Primary completion	26 January 2021
Estimated completion	26 January 2021
Sites	8 locations across Canada, United States

Drugs / interventions tested

KPT-9274 — full drug profile →
Niacin ER
Nivolumab (nivolumab) — full drug profile →

Conditions studied

Solid Tumors — all drugs for Solid Tumors →
NHL — all drugs for NHL →

Sponsor

Karyopharm Therapeutics Inc — full company profile →

Who can join

18 and older, any sex, with Solid Tumors or NHL. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Maximum Tolerated Dose (MTD) for KPT-9274 Primary · From start of study drug administration up to 44 weeks

The MTD was defined as the highest dose at which less than or equal to (\<=) 1 participant experienced a dose limiting toxicity (DLT) in Cycle 1. A DLT was defined as an adverse event (AE) or abnormal laboratory value occurring within the first 28 days of treatment of KPT-9274, excluding those clearly caused by underlying disease, disease progression, or external factors.

Group	Value	95% CI
Part A: KPT-9274 10mg	NA
Part A: KPT-9274 20mg	NA
Part A: KPT-9274 30mg	NA
Part A: KPT-9274 40mg	NA
Part A: KPT-9274 40mg BIW	NA
Part B: KPT-9274 30mg + Niacin 500mg	NA
Part B: KPT-9274 40mg + Niacin 500mg	NA
Part B: KPT-9274 60mg + Niacin 500mg	NA
Part B: KPT-9274 80mg + Niacin 500mg	NA
Part B: KPT-9274 100mg + Niacin 500mg	NA
Part C: KPT-9274 20mg + Nivolumab 480mg	NA
Part C: KPT-9274 30mg + Nivolumab 480mg	NA

Number of Dose Limiting Toxicities (DLT) Experienced by Participants Primary · At Cycle 1 only (28-day cycle)

A DLT was defined as an AE or abnormal laboratory value occurring within the first 28 days of KPT-9274 treatment, excluding those clearly caused by underlying disease, disease progression, or extraneous causes, and meets any of the criteria for defining dose limiting toxicities.

Group	Value	95% CI
Part A: KPT-9274 10mg	0
Part A: KPT-9274 20mg	0
Part A: KPT-9274 30mg	0
Part A: KPT-9274 40mg	1
Part A: KPT-9274 40mg BIW	0
Part B: KPT-9274 30mg + Niacin 500mg	0
Part B: KPT-9274 40mg + Niacin 500mg	0
Part B: KPT-9274 60mg + Niacin 500mg	0
Part B: KPT-9274 80mg + Niacin 500mg	2
Part B: KPT-9274 100mg + Niacin 500mg	0
Part C: KPT-9274 20mg + Nivolumab 480mg	0
Part C: KPT-9274 30mg + Nivolumab 480mg	0

Number of Participants With Adverse Event (AE) of Severity Grade >= 3 or 4, Serious AEs, and AEs Leading to Treatment Discontinuation Primary · From start of study drug administration up to 49 weeks

The AE severity was graded on a scale from 1 to 4 using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03; any events not specifically listed in the scale were defined as: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe or medically significant; Grade 4 is life-threatening. An SAE was any untoward medical occurrence that at any dose met one, more of the following criteria: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a

Maximum Grade 3/4 AEs

Group	Value	95% CI
Part A: KPT-9274 10mg	1
Part A: KPT-9274 20mg	2
Part A: KPT-9274 30mg	5
Part A: KPT-9274 40mg	7
Part A: KPT-9274 40mg BIW	3
Part B: KPT-9274 30mg + Niacin 500mg	2
Part B: KPT-9274 40mg + Niacin 500mg	3
Part B: KPT-9274 60mg + Niacin 500mg	10
Part B: KPT-9274 80mg + Niacin 500mg	7
Part B: KPT-9274 100mg + Niacin 500mg	1
Part C: KPT-9274 20mg + Nivolumab 480mg	1
Part C: KPT-9274 30mg + Nivolumab 480mg	4

Maximum Grade 4 AEs

Group	Value	95% CI
Part A: KPT-9274 10mg	0
Part A: KPT-9274 20mg	0
Part A: KPT-9274 30mg	1
Part A: KPT-9274 40mg	3
Part A: KPT-9274 40mg BIW	0
Part B: KPT-9274 30mg + Niacin 500mg	1
Part B: KPT-9274 40mg + Niacin 500mg	0
Part B: KPT-9274 60mg + Niacin 500mg	0
Part B: KPT-9274 80mg + Niacin 500mg	0
Part B: KPT-9274 100mg + Niacin 500mg	1
Part C: KPT-9274 20mg + Nivolumab 480mg	0
Part C: KPT-9274 30mg + Nivolumab 480mg	0

Serious AEs

Group	Value	95% CI
Part A: KPT-9274 10mg	0
Part A: KPT-9274 20mg	2
Part A: KPT-9274 30mg	2
Part A: KPT-9274 40mg	3
Part A: KPT-9274 40mg BIW	0
Part B: KPT-9274 30mg + Niacin 500mg	1
Part B: KPT-9274 40mg + Niacin 500mg	1
Part B: KPT-9274 60mg + Niacin 500mg	6
Part B: KPT-9274 80mg + Niacin 500mg	1
Part B: KPT-9274 100mg + Niacin 500mg	1
Part C: KPT-9274 20mg + Nivolumab 480mg	1
Part C: KPT-9274 30mg + Nivolumab 480mg	2

AEs Leading to Study Treatment Discontinuation

Group	Value	95% CI
Part A: KPT-9274 10mg	0
Part A: KPT-9274 20mg	0
Part A: KPT-9274 30mg	1
Part A: KPT-9274 40mg	2
Part A: KPT-9274 40mg BIW	1
Part B: KPT-9274 30mg + Niacin 500mg	0
Part B: KPT-9274 40mg + Niacin 500mg	1
Part B: KPT-9274 60mg + Niacin 500mg	0
Part B: KPT-9274 80mg + Niacin 500mg	2
Part B: KPT-9274 100mg + Niacin 500mg	0
Part C: KPT-9274 20mg + Nivolumab 480mg	0
Part C: KPT-9274 30mg + Nivolumab 480mg	0

Adverse events — posted to ClinicalTrials.gov

Time frame: From start of study drug administration up to 49 weeks. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Part A: KPT-9274 10mg

Serious: 0/3 (0%)

Deaths: 2/3

Part A: KPT-9274 20mg

Serious: 2/3 (67%)

Deaths: 2/3

Part A: KPT-9274 30mg

Serious: 2/5 (40%)

Deaths: 3/5

Part A: KPT-9274 40mg

Serious: 3/7 (43%)

Deaths: 5/7

Part A: KPT-9274 40mg BIW

Serious: 0/5 (0%)

Deaths: 1/5

Part B: KPT-9274 30mg + Niacin 500mg

Serious: 1/3 (33%)

Deaths: 3/3

Part B: KPT-9274 40mg + Niacin 500mg

Serious: 1/4 (25%)

Deaths: 3/4

Part B: KPT-9274 60mg + Niacin 500mg

Serious: 6/12 (50%)

Deaths: 6/12

Part B: KPT-9274 80mg + Niacin 500mg

Serious: 1/7 (14%)

Deaths: 4/7

Experimental: Part B: KPT-9274 100mg + Niacin 500mg

Serious: 1/1 (100%)

Deaths: 1/1

Part C: KPT-9274 20mg + Nivolumab 480mg

Serious: 1/1 (100%)

Deaths: 1/1

Part C: KPT-9274 30mg + Nivolumab 480mg

Serious: 2/5 (40%)

Deaths: 2/5

Part C: KPT-9274 40mg + Nivolumab 480mg

Serious: 2/4 (50%)

Deaths: 3/4

Serious adverse events (29 terms)

Reaction	System	Part A: KPT-9274 10mg	Part A: KPT-9274 20mg	Part A: KPT-9274 30mg	Part A: KPT-9274 40mg	Part A: KPT-9274 40mg BIW	Part B: KPT-9274 30mg + Ni…	Part B: KPT-9274 40mg + Ni…	Part B: KPT-9274 60mg + Ni…	Part B: KPT-9274 80mg + Ni…	Experimental: Part B: KPT-…	Part C: KPT-9274 20mg + Ni…	Part C: KPT-9274 30mg + Ni…	Part C: KPT-9274 40mg + Ni…
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Small intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Death	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Pleural effusion	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Haematoma	Vascular disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Bradycardia	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Sinus tachycardia	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Gastrointestinal haemorrhage	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Klebsiella bacteraemia	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—
Sepsis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—
Cardiac murmur	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Hypoglycaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Tumour pain	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—	—	—	—	—	—	—
Intracranial mass	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Hyperbilirubinaemia	Hepatobiliary disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Portal vein thrombosis	Hepatobiliary disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Campylobacter infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—

Other adverse events (154 terms — click to expand)

Reaction	System	Part A: KPT-9274 10mg	Part A: KPT-9274 20mg	Part A: KPT-9274 30mg	Part A: KPT-9274 40mg	Part A: KPT-9274 40mg BIW	Part B: KPT-9274 30mg + Ni…	Part B: KPT-9274 40mg + Ni…	Part B: KPT-9274 60mg + Ni…	Part B: KPT-9274 80mg + Ni…	Experimental: Part B: KPT-…	Part C: KPT-9274 20mg + Ni…	Part C: KPT-9274 30mg + Ni…	Part C: KPT-9274 40mg + Ni…
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Flushing	Vascular disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Weight decreased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Hyperbilirubinaemia	Hepatobiliary disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Sinus tachycardia	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Nasopharyngitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—
Lipase increased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—
Hypomagnesaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Hypoalbuminaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Hyponatraemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Muscular weakness	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Muscle spasms	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Abdominal discomfort	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Hypercalcaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Hypophosphataemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Leukopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Tachycardia	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Hypothyroidism	Endocrine disorders	—	—	—	—	—	—	—	—	—	—	—	—	—
Dyspepsia	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—

Most-reported serious reactions: Anaemia, Abdominal pain, Thrombocytopenia, Small intestinal obstruction, Death, Dyspnoea, Pleural effusion, Haematoma.

Data from ClinicalTrials.gov NCT02702492 adverse events section.

Sponsor's own description

This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

NAD<sup>+</sup> metabolism: pathophysiologic mechanisms and therapeutic potential.
Xie N, Zhang L, Gao W, Huang C, et al · · 2020 · cited 744× · PMID 33028824 · DOI 10.1038/s41392-020-00311-7
NAD<sup>+</sup> metabolism, stemness, the immune response, and cancer.
Navas LE, Carnero A. · · 2021 · cited 379× · PMID 33384409 · DOI 10.1038/s41392-020-00354-w
Targeting Rho GTPase Signaling Networks in Cancer.
Clayton NS, Ridley AJ. · · 2020 · cited 136× · PMID 32309283 · DOI 10.3389/fcell.2020.00222
Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy.
Galli U, Colombo G, Travelli C, Tron GC, et al · · 2020 · cited 122× · PMID 32477131 · DOI 10.3389/fphar.2020.00656
PAK4 inhibition improves PD-1 blockade immunotherapy.
Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, et al · · 2020 · cited 119× · PMID 34368780 · DOI 10.1038/s43018-019-0003-0
Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.
Abu Aboud O, Chen CH, Senapedis W, Baloglu E, et al · · 2016 · cited 118× · PMID 27390344 · DOI 10.1158/1535-7163.mct-16-0197
Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes.
Neggers JE, Kwanten B, Dierckx T, Noguchi H, et al · · 2018 · cited 83× · PMID 29402884 · DOI 10.1038/s41467-017-02349-8
Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer Therapy.
Heske CM. · · 2019 · cited 80× · PMID 32010616 · DOI 10.3389/fonc.2019.01514

Verify or expand the search:

Other trials of KPT-9274

Trials testing the same drug.

NCT04914845 — KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia · Phase 1 · completed

Other recruiting trials for Solid Tumors

Currently open trials in the same condition.

NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07395258 — A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Differe · Phase 1 · recruiting
NCT07505069 — Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors · EARLY_PHASE1 · recruiting

Other Karyopharm Therapeutics Inc trials

Trials by the same sponsor.

NCT04854434 — A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previo · Phase 2 · terminated
NCT04768881 — Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma · Phase 2 · terminated
NCT04421378 — A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma · Phase 1, PHASE2 · terminated
NCT04355676 — Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COV · Phase 2 · withdrawn
NCT04349098 — Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02702492 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Karyopharm Therapeutics Inc
Last refreshed: 25 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02702492.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing